Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 3
Submit an article Journal homepage
253
Views
36
CrossRef citations to date
0
Altmetric
Research Article

Preferentially Expressed Antigen of Melanoma (PRAME) in the Development of Diagnostic and Therapeutic Methods for Hematological Malignancies

Maiko Matsushita Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Mail code 160-8582 Tokyo, Japan
,
Rie Yamazaki Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Mail code 160-8582 Tokyo, Japan
,
Hideyuki Ikeda Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Mail code 160-8582 Tokyo, Japan
&
Yutaka Kawakami Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Pages 439-444 | Published online: 01 Jul 2009

  • Lowenberg, B., Downing, I.R. and Burnett, A. (1999) "Acute myeloid leukemia [see comments]", N. Engl. J. Med. 341, 1051-1062 [published erratum appears in N. Engl. J. Med. (1999) 341 (19),1484].
  • Ikeda, H., Lethe, B., Lehmann, F, van Baren, N., Baurain, I.F., de Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T. and Coulie, P.G. (1997) "Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor", Immunity 6, 199-208.
  • Neumann, E., Engelsberg, A., Decker, J., Storkel, S., Jaeger, E., Huber, C. and Seliger, B. (1998) "Heterogeneous expression of the tumor-associated antigens RAGE-1, FRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?", Cancer Res. 58, 4090-4095.
  • Cure, A.O., Stocken, E., Arden, K.C., Boyer, A.D., 'Wars, C.S., Scanlan, M.J., Old, L.J. and Chen, Y.T. (2000) "CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis", Int. J. Cancer 85, 726-732.
  • van Baren, N., Chambost, H., Ferrant, A., Michaux, L., Ikeda, H., Millard, I., Olive, D., Boon, T. and Coulie, R.G. (1998) "FRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells", Br. J. Haematol. 102, 1376-1379.
  • Greiner, J., Ringhoffer, M., Simikopinko, O., Szmaragowska, A., Huebsch, S., Maurer, U., Bergmann, L. and Schmitt, M. (2000) "Simultaneous expression of different immunogenic antigens in acute myeloid leukemia", Exp. Hematol. 28, 1413-1422.
  • Matsushita, M., Ikeda, H., Kizaki, M., Okamoto, S., Ogasawara, M., Ikeda, Y. and Kawakami, Y (2001) "Quantitative monitoring of the FRAME gene for the detection of minimal residual disease in leukaemia", Br. J. Haematol. 112, 916-926.
  • van Baren, N., Brasseur, F., Godelaine, D., Harnes, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G.C., Bakkus, M., Thielemans, K. and Boon, T. (1999) "Genes encoding tumor-specific antigens are expressed in human myeloma cells", Blood 94, 1156-1164.
  • Pellat-Deceunynck, C., Mellerin, M.P., Labarriere, N., lego, G., Moreau-Aubry, A., Harousseau, J.L., Jotereau, F. and Bataille, R. (2000) "The cancer germ-line genes MAGE-1, MAGE-3 and FRAME are commonly expressed by human myeloma cells", EUT. J. Immunol. 30, 803-809.
  • Watari, K., Tojo, A., Nagamura-Inoue, T., Nagamura, F., Takeshita, A., Fukushima, T., Motoji, T., Tani, K. and Asano, S. (2000) "Identification of a melanoma antigen, FRAME, as a BCR/ABLinducible gene", FEBS Lett. 466, 367-371.
  • Gerard, C.J., Olsson, K., Ramanathan, R., Reading, C. and Hanania, E.G. (1998) "Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards", Cancer Res. 58, 3957-3964.
  • Mensink, E., van de Locht, A., Schattenberg, A., Linders, E., Schaap, N., Geurts van Kessel, A. and De Witte, T. (1998) "Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR", Br. J. Haematol. 102, 768-774.
  • Pongers-Willemse, M.J., Vertagen, O.J., Tibbe, G.I., Wijkhuijs, A.I., de Haas, V, Roovers, E., van der School, C.E. and van Dongen, I.J. (1998) "Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes", Leukemia 12, 2006-2014.
  • Ballerini, P., Landman Parker, I., Laurendeau, I., Olivi, M., Vidaud, M., Adam, M., Leverger, G., Gerota, I., Cayre, Y.E. and Bieche, I. (2000) "Quantitative analysis of TEL/AMLl fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia", Leukemia 14, 1526-1528.
  • Drunat, S., Olivi, M., Brunie, G., Grandchamp, B., Vilmer, E., Bieche, I. and Cave, H. (2001) "Quantification of TEL-AMLl transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia", Br. J. Haematol. 114, 281-289.
  • Kreuzer, K.A., Saborowski, A., Lupberger, I., Appelt, C., Na, I.K., Ie Coutre, P. and Schmidt, C.A. (2001) "Fluorescent 5/-exonuclease assay for the absolute quantification of Wilms' tumour gene (WTl) mRNA: implications for monitoring human leukaemias", Br. J. Haematol 114, 313-318.
  • Kawakami, Y. (1998) "Immunotherapy using T cell defined tumor antigens for melanoma", Microbiol Immunol. 42, 801-813.
  • Salgaller, M.L., Marincola, F.M., Cormier, I.N. and Rosenberg, S.A. (1996) "Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides", Cancer Res. 56, 4749-4757.
  • lager, E., Ringhoffer, M., Dienes, H.P., Arand, M., Karbach, I., lager, D., Ilsemann, C., Hagedorn, M., Oesch, F. and Knuth, A. (1996) "Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo". Int. J. Cancer 67, 54-62.
  • Cormier, J.N., Salgaller, M.L., Prevette, T., Barracchini, K.C., Rivoltini, L., Restifo, N.P., Rosenberg, S.A. and Marincola, EM. (1997) "Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]", Cancer J. Sci. Am. 3, 37-44.
  • Rosenberg, S.A., Yang, I.C., Schwartzentruber, D.I., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.I., Wunderlich, I.R., Parkhurst, M.R., Kawakami, Y, Seipp, C.A., Einhorn, I.H. and White, D.E. (1998) "Immunologie and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]", Nat. Med. 4, 321-327.
  • Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y, Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]", Nat. Med. 4, 328-332.
  • Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Ionuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brocker, E.B., Steinman, R.M., Enk, A., Kampgen, E. and Schuler, G. (1999) "Vaccination with mage-3Al peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma", J. Exp. Med. 190, 1669-1678.
  • Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B. and Levy, R. (1997) "Tumorspecific idiotype vaccines in the treatment of patients with B- cell lymphoma-long-term results of a clinical trial", Blood 89, 3129-3135.
  • Bosch, G.I., Ioosten, A.M., Kessler, I.H., Melief, C.J. and Leeksma, O.C. (1996) "Recognition of BCR-ABL positive leukemic blasts by human CXM + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide", Blood 88, 3522-3527.
  • Mannering, S.I., McKenzie, J.L., Fearnley, D.B. and Hart, D.M. (1997) "HLA-DRl-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates", Blood 90, 290-297.
  • Nieda, M., Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Tadokoro, K. and Juji, T. (1998) "Dendritic cells stimulate the expansion of bcr-abl specific CDS + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia", Blood 91, 977-983.
  • Yotnda, P., Firat, H., Garcia-Pons, F., Garcia, Z., Courra, G., Vernant, J.P., Lemonnier, F.A., Leblond, V. and LangladeDemoyen, P. (1998) "Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia", J. Clin. Investig. 101, 2290-2296.
  • Molldrem, J., Dermime, S., Parker, K., Iiang, Y.Z., Mavroudis, D., Hensel, N., Fukushima, P. and Barren, A.J. (1996) "Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells", Blood 88, 2450-2457.
  • Molldrem, J.J., Lee, P.P., Wang, C., Felio, K., Kantarjian, H.M., Champlin, R.E. and Davis, M.M. (2000) "Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia", Nat. Med. 6, 1018-1023.
  • Ohminami, H., Yasukawa, M. and Fuji ta, S. (2000) "HLA class !-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WTl peptide", Blood 95, 286-293.
  • Vonderheide, R.H., Hahn, W.C., Schultze, J.L. and Nadler, L.M. (1999) 'The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes", Immunity 10, 673-679.
  • Arai, J., Yasukawa, M., Ohminami, H., Kakimoto, M., Hasegawa, A. and Fujita, S. (2001) "Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes", Blood 97, 2903-2907.
  • Goulmy, E., Schipper, R., Pool, J., Blokland, E., Falkenburg, I.H., Vossen, J., Grathwohl, A., Vogelsang, G.B., van Houwelingen, H.C. and van Rood, J.J. (1996) "Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation [see comments]", N. Engl. J. Med. 334,281-285.
  • Warren, E.H., Greenberg, P.D. and Riddell, S.R. (1998) "Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution", Blood 91, 2197-2207.
  • Kessler, J.H., Beekman, NJ., Bres-Vloemans, S.A., Verdijk, P., van Veelen, P.A., Kloosterman-Joosten, A.M., Vissers, D.C., ten Bosch, GJ., Kester, M.G., Sijts, A., Wouter Drijfhout, J., Ossendorp, P., Offringa, R. and Melief, C.J. (2001) "Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasomemediated digestion analysis", J. Exp. Med. 193, 73-88.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.